Objective-Perivascular adipose tissue (PVAT) exerts an anticontractile effect in response to various vasoconstrictor agonists, and this is lost in obesity. A recent study reported that bariatric surgery reverses the damaging effects of obesity on PVAT function. However, PVAT function has not been characterized after weight loss induced by caloric restriction, which is often the first line treatment for obesity. Approach and Results-Contractility studies were performed using wire myography on small mesenteric arteries with and without PVAT from control, diet-induced obese, calorie restricted and sustained weight loss rats. Changes in the PVAT environment were assessed using immunohistochemistry. PVAT from healthy animals elicited an anticontractile effect in response to norepinephrine. This was abolished in diet-induced obesity through a mechanism involving increased local tumor necrosis factor-α and reduced nitric oxide bioavailability within PVAT. Sustained weight loss led to improvement in PVAT function associated with restoration of adipocyte size, reduced tumor necrosis factor-α, and increased nitric oxide synthase function. This was associated with reversal of obesity-induced hypertension and normalization of plasma adipokine levels, including leptin and insulin. Conclusions-We have shown that diet-induced weight loss reverses obesity-induced PVAT damage through a mechanism involving reduced inflammation and increased nitric oxide synthase activity within PVAT. These data reveal inflammation and nitric oxide synthase, particularly endothelial nitric oxide synthase, as potential targets for the treatment of PVAT dysfunction associated with obesity and metabolic syndrome. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
O besity is one of the major causes of illness and death in the world, and it is a significant public health burden currently affecting an estimated half a billion adults and 40 million children globally. 1 It is associated with many comorbidities, and overwhelming evidence supports the importance of obesity in the pathogenesis and progression of cardiovascular disease. 2 The rapidly increasing gap between the availability of medical therapies and the steadily rising rates of obesity emphasize the need for investigation into novel therapies to prevent the devastating effects of being overweight.
Healthy perivascular adipose tissue (PVAT) exerts an anticontractile effect on adjacent arteries. [3] [4] [5] that is lost in both rodent models [6] [7] [8] [9] and human obesity and the metabolic syndrome, 5, 10 suggesting that changes in PVAT function and morphology may contribute to vascular dysfunction associated with increased body weight 5 and diabetes mellitus. 11, 12 The most obvious treatment for obesity is weight loss (WL), which can be achieved through lifestyle changes and surgical methods. Bariatric surgery is an established method of reducing obesity-associated morbidity, and the cardiovascular benefits have been clearly demonstrated. 13, 14 The mechanisms that underlie these improvements are unclear but are likely to be a consequence of improvements in inflammatory and adipokine profiles. [15] [16] [17] Our studies demonstrate that bariatric surgery can reverse obesity-induced PVAT damage 6 months after surgery through reduction of adipose inflammation and increasing local adiponectin and nitric oxide (NO) bioavailability. 10 This correlated with reduced blood pressure and improvements in lipid profiles and blood glucose levels, suggesting that the restoration of PVAT function could contribute to the cardiovascular benefits of losing weight.
Bariatric surgery is not suitable for all obese patients meaning that simple lifestyle measures such as caloric restriction and increased exercise should not be ignored and are often the first line in treatment for obesity. 18 Few studies have been specially designed to determine the effects of WL produced by dietary intervention in obesity; however, the majority of clinical trials and animal studies have reported a beneficial effect of diet-induced WL on blood pressure 13, 19, 20 and adipokine balance, [20] [21] [22] along with improvements in the inflammatory profile. 9, 22 July 2016 Investigation into the mechanisms involved in any improvement in PVAT function could lead to identification of much needed novel therapeutic targets for the treatment of obesity-related hypertension and cardiovascular disease. Therefore, this study was designed to explore changes in the PVAT environment that occur in obesity and to investigate the effects of diet-induced WL on PVAT anticontractile function. This study tested the hypothesis that diet-induced WL would lead to the restoration of PVAT function through changes in local inflammation and NO bioavailability. We report that dietinduced obesity perturbs PVAT function through a mechanism involving inflammation and nitric oxide synthase (NOS) and the PVAT damage can be reversed by sustained WL and associated reduction in adipose inflammation and increased NOS availability.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

WL Reversed Cardiometabolic Damage Induced by High-Fat Diet
There were no significant differences in body weight of the rats before starting their respective diets (P=0.39). After 16 weeks of consuming the 45% fat diet (high fat diet [HFD]), animals were significantly heavier than controls (P<0.01, Figure 1 ). Two groups of obese animals (WL and weight maintenance [WM]) were then subjected to caloric restriction for 4 weeks to induce WL. Caloric restriction produced a gradual reduction in body weight with animals losing an average of 130 g by week 20, at which time the average body weight was no longer different from control (P=0.57, Figure 1 ). Animals consuming the HFD continued to gain weight and were heavier than controls at week 20. To assess whether the vascular effects of WL were altered after the maintenance of body weight, rats in one of the groups (WM) were provided with 70 kcal/d for an additional 4 weeks and were able to maintain their body weight in comparison with control (P=0.89, Figure 1 ). Animals fed the HFD consumed significantly more calories than animals provided with a control diet (Figure I in the online-only Data Supplement, P<0.001), indicating that the animals did not compensate for the increased caloric content of the HFD by eating less.
The cardiometabolic profile of animals with dietary interventions is shown in Table. HFD produced insulin resistance without overt diabetes mellitus as shown by the increase in fasting plasma insulin levels (P<0.0001) without a change in blood glucose levels (P=0.83). Hyperinsulinemia was reversed after caloric restriction (P<0.0001), and this was sustained after the 4-week WM period (P<0.01) with no effect on blood glucose levels (P=0.85). Body weight did not have an effect on plasma total adiponectin levels (P=0.13). Plasma leptin levels were significantly increased compared with those of controls after 8 weeks of high-fat feeding (P<0.01, data not shown) and were 142% greater than control by week 20 (P<0.0001). Hyperleptinemia was reversed after caloric restriction (P<0.001), and this reduction was sustained after the 4-week WM period (P<0.001).
Systolic and diastolic blood pressure did not change during the 20-week period in animals fed control diet. High-fat feeding induced significant increases in both systolic (P<0.0001) and diastolic (P<0.0001) blood pressure. Increases in systolic blood pressure were reversed after 4-week WL (control versus WL: P=0.06), and this was maintained during the WM period (control versus WM: P=0.09). Diastolic blood pressure was reduced after WL; however, it remained significantly elevated compared with control (P<0.01). Maintenance of body weight led to complete reversal of the hypertensive phenotype as diastolic blood pressure decreased to control levels (control versus WM: P=0.37). Significant tachycardia was observed in diet-induced obesity (control: 299±5.0 bpm versus obese: 335±6.9 bpm; P<0.0001). Caloric restriction induced transient bradycardia (WL: 246±10.9 bpm, P<0.0001); however, heart rate returned to control levels in following WM (294±8.1 bpm, P=0.56) suggesting that the reduced heart rate was a consequence of extreme WL.
Anticontractile Capacity of PVAT Is Restored After Sustained WL
The presence of PVAT did not alter the contractile response evoked by stimulation with high-potassium physiological salt solution in any of the animal models used ( Figure II The presence of PVAT reduced the vasoconstrictor response to norepinephrine in lean controls (P<0.0001, Figure 2A ). However, the presence of PVAT did not alter the contractile response in vessels isolated from animals provided HFD (P=0.21, Figure 2B ) and the contractile response of vessels with PVAT to norepinephrine was increased compared with controls (P=0.03, Figure IIIA in the online-only Data Supplement), indicating that dietinduced obesity diminished the anticontractile capacity of PVAT. WL induced by 50% caloric restriction did not reverse obesity-induced loss of PVAT anticontractile effect because responses were unaltered by the presence of PVAT (P=0.14, Figure 2C ) and the vasoconstrictor response to norepinephrine remained elevated compared with controls (P=0.01, Figure IIIA in the online-only Data Supplement). However, maintenance of body weight for 4 weeks after caloric restriction led to restoration of the PVAT anticontractile function as the presence of PVAT reduced the contractile response to norepinephrine (P<0.0001, Figure 2D ) and the response of vessels with PVAT was no longer different to controls (P=0.35, Figure IIIA in the online-only Data Supplement). Changes in body weight had no effect on the vasoconstrictor response to norepinephrine in endothelium intact vessels lacking PVAT (P=0.14, Figure IIIB in the online-only Data Supplement).
Adipocyte Hypertrophy and PVAT Inflammation Are Reduced by WL
Obesity produced an increase in adipocyte cross-sectional area (P<0.0001), which was reduced but not completely reversed after caloric restriction (obese versus WL: P<0.0001, control versus WL: P<0.0001). However, complete restoration of adipocyte size was observed after a 4-week WM period (control versus WM: P=0.67, Figure 3A and 3B). The change in adipocyte area positively correlated with change in body weight (r=0.73, P<0.0001).
Eosinophil number within PVAT was reduced in dietinduced obesity (P<0.0001). Eosinophil number increased after caloric restriction but levels were not significantly different to either control or obese (P>0.05). However, eosinophil levels within PVAT were restored by WM (P=0.67, Figure 3C ). Moreover, the number of eosinophils within PVAT negatively correlated with body weight (r=−0.41, P=0.04) Tumor necrosis factor-α (TNFα) staining intensity was significantly increased in PVAT from obese animals compared with control (P<0.0001) and staining remained high after 4-week caloric restriction (control versus WL: P=0.0019 and obese versus WL: P=0.07). However, the increased TNFα immunostaining was reversed by sustained WL (control versus WM: P=0.11 and obese versus WM: P<0.0001, Figure 4 ).
Immunostaining for CD68 + cells was used to detect the total number of macrophages within PVAT ( Figure 5 ). Macrophage infiltration occurred in diet-induced obesity (control versus obese: P<0.0001) and was decreased after caloric restriction (control versus WL: P>0.05 and obese versus WL: P=0.02). However, macrophage number was further reduced to control levels after 4-week WM (control versus WM: P=0.80 and WL versus WM: P=0.0062).
PVAT-Derived NO Contributes to Restoration of PVAT Anticontractility After Maintenance of Body Weight
Total endothelial nitric oxide synthase (eNOS) expression within PVAT ( Figure 6A and 6B) was reduced by diet-induced obesity (P=0.029) and remained reduced after four-week caloric restriction (P=0.04). WM increased eNOS expression although levels were not significantly different to either control (P=0.94) or obese (P=0.34). Incubation of arteries with intact endothelium but lacking PVAT with the NOS inhibitor, NG-monomethyl-l-arginine did not alter the vasoconstrictor response to norepinephrine (P=0.86, data not shown). However, the presence of N Gmonomethyl-l-arginine increased the vasoconstrictor response to norepinephrine in PVAT intact vessels taken from control animals (P<0.0001, Figure 6C ). Incubation of PVAT intact vessels with N G -monomethyl-l-arginine reduced the contractile response to norepinephrine in obesity (P=0.0067, Figure 6D ) but had no effect after WL induced by caloric restriction (P=0.06, Figure 6E ). However, the effects of NOS inhibition were restored after WM as an increase in the contractile response was observed in vessels with PVAT in the presence of N Gmonomethyl-l-arginine (P=0.0012, Figure 6F ). Moreover, the presence of PVAT did not alter vasodilation in response to carbachol (P=0.81, Figure IV in the online-only Data Supplement).
Discussion
This study investigated the effects of obesity and diet-induced WL on the anticontractile properties of PVAT. The main findings were (1) diet-induced obesity perturbs PVAT function through a mechanism involving downregulation of NOS and increased inflammation, (2) the impaired anticontractile effect of PVAT associated with obesity can be ameliorated by sustained WL, and (3) sustained WL improves PVAT anticontractile function by reducing adipose inflammation and increasing NOS availability. These observations advance our understanding of how changes in the PVAT environment contribute to vascular dysfunction associated with obesity and how these may be reversed to restore normal PVAT function.
Animals consuming the HFD rapidly gained weight becoming significantly heavier than those fed control diet indicative of the development of obesity. In agreement with human obesity 23 and rat models of diet-induced obesity, 21, 24, 25 high-fat feeding was associated with hypertension and hyperleptinemia. In contrast to the human phenotype, blood glucose levels were unaltered in obesity; however, overt hyperglycaemia has rarely been reported in studies using Sprague-Dawley rats 26 and in agreement with our data, insulin resistance is common and its severity seems to be dependent on the fat content of the diet and duration of feeding. 27 The initial caloric restriction to 40 kcal/d was chosen to mimic human dieting 28 and successfully produced a significant reduction in body weight during the 4-week period, consistent with that observed in other rodent models. 21, 22, 29 Consistent with previous studies reporting the beneficial effects of WL on cardiovascular risk factors, 13, 21, 30 we also found circulating leptin and insulin levels were reduced to normal at the end of the 4-week caloric restriction period. The increases in systolic blood pressure associated with obesity were reversed after caloric restriction; however, diastolic blood pressure was only restored to control levels at the end of the 4-week WM period, suggesting that reversal of obesity-induced hypertension required sustained WL. The cause of the difference in the effect of caloric restriction on systolic versus diastolic blood pressure is unclear but may be a consequence of changes in peripheral resistance because this directly influences diastolic blood pressure. This is supported by the data presented in this study, as obesity-associated changes in the PVAT environment were still present after 4-week caloric restriction, so increased diastolic blood pressure in WL animals might reflect the reduced PVAT anticontractile capacity.
In line with studies of small arteries taken from obese patients 5, 10 and rodent models of obesity, [7] [8] [9] 31 we found that the anticontractile effect of PVAT was lost in the rat model of diet-induced obesity. Obesity has been described as the perfect storm as the storage of excess energy in adipocytes leads to hypertrophy and subsequent hypoxia, resulting in chronic inflammation and abnormalities in adipocyte function. 2 Adipocyte hypertrophy is one of the major hallmarks of obesity and similar to previous studies, 5, 9, 10 we found that the cross-sectional area of adipocytes from mesenteric PVAT of obese animals was greatly increased. It has been shown that blood supply to adipocytes does not increase to compensate for enlarged adipocyte size, 32 and hypertrophied adipocytes are larger than the normal diffusion distance of oxygen within tissues 33 suggesting that obese adipocytes exist in a state of hypoxia. 34 This results in the development of a chronic inflammatory state within the adipose tissue with increased production of proinflammatory cytokines, such as TNFα, 5, 10, 35 which was observed in PVAT from obese animals.
Increased adipocyte size and subsequent inflammation within PVAT contribute to the obesity-induced loss of PVAT anticontractile effect. This is supported by previous work within our laboratory showing that experimental hypoxia, produced by gassing arteries with 95% nitrogen and 5% CO 2 for 2.5 hours, significantly attenuated the anticontractile effect of PVAT in both rat 5, 36 and mouse 37 mesenteric arteries through a mechanism that involved increased TNFα and interleukin-6. However, the damaging effects of obesity on PVAT function could not be reversed by incubation of arteries from obese patients with an anti-TNFα antibody, 5 suggesting that chronic inflammation produces changes in adipocyte function and subsequent release of adipokines.
The origins of proinflammatory cytokines within PVAT have not been explored; however, previous studies have suggested increased levels of TNFα are a consequence of both increased adipokine secretion from the adipocytes and increased macrophage infiltration into the adipose tissue. 38, 39 Our data support a role for increased macrophage infiltration as the number of CD68 + cells within PVAT was increased in obesity. We accept that CD68 + may not be entirely macrophage specific as discussed previously by Kunisch and it is feasible that increased adipose fibrosis may contribute to the changes observed. 41 However, studies using a mouse model of macrophage ablation showed a key role for macrophage activation in the loss of anticontractile effect when healthy PVAT is subjected to inflammatory insults, 36 suggesting that the observed infiltration of proinflammatory macrophages contribute to the loss of PVAT anticontractile capacity in our animal model of diet-induced obesity. Moreover, a recent study reported increased macrophage infiltration in the aortic PVAT of obese mice when identified using either CD68 or F4/80. 42 Eosinophils play a role in sustaining anti-inflammatory M2 macrophages within the adipose tissue, 43 and recent studies within our laboratory have shown a loss of PVAT anticontractile effect in ΔdbGATA-F2 mice, which are deficient in eosinophils. 44 We show a reduction in the number of eosinophils within PVAT in diet-induced obesity and an inverse correlation with body weight, consistent with reports in perigonadal adipose tissue from obese mice. 43 This suggests that loss of eosinophils may contribute to the obesity-induced loss of PVAT anticontractile function, although the mechanism is currently unclear.
Consistent with our data showing reduced eNOS levels in PVAT in obesity, several studies have reported decreased eNOS expression in white adipose tissue taken from animal models of obesity, 45, 46 suggesting that this may contribute to the observed reduction in NO activity. Moreover, TNFα activity has been shown to induce eNOS downregulation in rodent white adipose tissue 45 and contribute to endothelial dysfunction via downregulation of NOS in small mesenteric arteries, 47 suggesting that changes in eNOS activity could be the link between increased inflammation in PVAT and reduced function.
Previous studies in human subcutaneous small arteries reported NOS inhibition had no effect on PVAT function in human obesity. 5, 10 We found that NOS inhibition produced a reduction in vascular contractility in obesity, suggesting that changes in NOS activity and subsequent reduced NO bioavailability contribute to the attenuation of PVAT function. The reasons for this are unclear, but increased levels of reactive oxygen species have been reported to lead to the uncoupling of eNOS resulting in the formation of perioxynitrite rather than NO. 31, 48 This is supported by previous data from our laboratory showing free radical scavengers can rescue PVAT anticontractile function in human obesity 10 and the recent work of Xia et al 42 showing eNOS uncoupling within aortic PVAT from high-fat fed mice.
A previous study reported that bariatric surgery could restore PVAT function by a reduction in adipose inflammation and increasing NO bioavailability 10 ; therefore, we investigated whether WL induced by dietary restriction could produce similar effects. To separate the effects of reduced energy intake and the physiological effects of WL, PVAT function was explored after a 4-week caloric restriction period and after a WM period, in which animals were maintained on a healthy caloric intake for a further 4 weeks leading to sustained WL. We found that the anticontractile effect of PVAT was restored after sustained WL, and this was associated with reversal of hypertension and reduction in markers of the metabolic syndrome. However, the magnitude of the PVAT effect was not as pronounced as that observed in control animals providing evidence for the existence of parallel signaling pathways and PVAT-derived relaxing factors mediating PVAT function.
The improvement in PVAT function was associated with the restoration of adipocyte size to control levels, infiltration of eosinophils, decreased macrophage infiltration, reduction in PVAT TNFα, and restoration of eNOS expression suggesting that reduced inflammation facilitates restoration of PVAT function. The effects of diet-induced WL on adipose inflammation have not been widely studied; however, our findings are consistent with previous studies showing significant reductions in TNFα expression within mesenteric white adipose tissue after caloric restriction. 49 The increased eosinophil number within PVAT and their link to M2 macrophage stabilization 43 along with the reduced CD68 + cell staining indicate that reduction in macrophage infiltration may contribute to the restoration of PVAT function. Moreover, a recent study within our laboratory also supports the role of eosinophil infiltration in reversal of obesity-induced PVAT damage as reconstitution of eosinophils in ΔdbGATA-F2 mice restored the PVAT anticontractile capacity. 44 Along with the reduction in TNFα, we found that eNOS levels were restored after WM. This may be a consequence of the decreased macrophage numbers because this would reduce the high level of NO associated with uncoupling and also reduce TNFα production allowing restoration of normal eNOS expression. Moreover, inhibition of NOS increased the contractile response to norepinephrine, suggesting NOS function within PVAT was improved with a subsequent increase in NO bioavailability. This is supported by observations of increased plasma nitrite levels in obese patients after 12-week dietary intervention. 50 Moreover, enhanced NO bioavailability mediated increased endothelium-dependent relaxation after 10% WL in obese patients. 51 Improvements in vascular responses to l-arginine were also reported after WL and correlated with decline in serum TNFα, 52 suggesting a role for reduced TNFα in the restoration of NO.
We have shown that obesity is associated with a reversible reduction in NO bioavailability, and restoration of adipose eNOS levels may also contribute to reversal of the metabolic syndrome. Overexpression of eNOS in mice was found to prevent HFD-induced weight gain and hyperinsulinaeima and attenuate diet-induced adipocyte hypertrophy through increased metabolic rate. 46 Moreover, eNOS has been suggested to be a key regulator of metabolic homeostasis after observations that deletion of the eNOS gene induced insulin resistance through its effects on vasodilation and insulin signaling within the skeletal muscle. 53, 54 This suggests that the observed improvement in insulin sensitivity may be a consequence of improved eNOS function and a defect in NO synthesis may represent a mechanism linking metabolic syndrome and cardiovascular disease. Taken together, these data reveal eNOS as a new target for the treatment of PVAT dysfunction associated with obesity and the metabolic syndrome.
Four-week caloric restriction and its associated WL did not restore the anticontractile capacity of PVAT, even though systolic blood pressure returned to normal. Adipocyte hypertrophy and local inflammation were reduced within PVAT but not restored to control levels and NOS activity remained perturbed after WL. Moreover, diastolic blood pressure remained elevated suggesting that the damaging effects of obesity on PVAT function were not immediately reversed after return to control body weight and providing additional evidence for the role of PVAT in modulation of vascular tone.
Bariatric surgery led to complete restoration of the PVAT anticontractile capacity within 6 months that was associated with reduced systolic blood pressure even though patients were still obese and had enlarged adipocytes within PVAT. 10 Similar to our results after sustained WL, where the anticontractile effect was restored, a reduction in TNFα staining associated with increased local NO bioavailability was reported within PVAT after bariatric surgery, suggesting that reductions in local inflammation are key to restoration of the PVAT anticontractile capacity.
The results presented have shown that diet-induced obesity impairs PVAT anticontractile function through a mechanism involving increased TNFα and downregulation of NOS and that PVAT anticontractile function can be restored by sustained WL through reduction in local TNFα and increased NO availability. The findings support the targeting of inflammation and NOS for the treatment of PVAT dysfunction associated with obesity and the metabolic syndrome.
